Activation of the TGF- β1/EMT signaling pathway by claudin-1 overexpression reduces doxorubicin sensitivity in small cell lung cancer SBC-3 cells
Arch Biochem Biophys. 2023 Nov 18:109824. doi: 10.1016/j.abb.2023.109824. Online ahead of print.ABSTRACTSmall-cell lung cancer (SCLC), which accounts for about 15 % of all lung cancers, progresses more rapidly than other histologic types and is rarely detected at an operable early stage. Therefore, chemotherapy, radiation therapy, or their combination are the primary treatments for this type of lung cancer. However, the tendency to acquire resistance to anticancer drugs is a severe problem. Recently, we found that an intercellular adhesion molecule, claudin (CLDN) 1, known to be involved in the migration and invasion of lu...
Source: Archives of Biochemistry and Biophysics - November 20, 2023 Category: Biochemistry Authors: Yuri Nagaoka Kotone Oshiro Yuta Yoshino Toshiyuki Matsunaga Satoshi Endo Akira Ikari Source Type: research
Activation of the TGF- β1/EMT signaling pathway by claudin-1 overexpression reduces doxorubicin sensitivity in small cell lung cancer SBC-3 cells
Arch Biochem Biophys. 2023 Nov 19;751:109824. doi: 10.1016/j.abb.2023.109824. Online ahead of print.ABSTRACTSmall-cell lung cancer (SCLC), which accounts for about 15 % of all lung cancers, progresses more rapidly than other histologic types and is rarely detected at an operable early stage. Therefore, chemotherapy, radiation therapy, or their combination are the primary treatments for this type of lung cancer. However, the tendency to acquire resistance to anticancer drugs is a severe problem. Recently, we found that an intercellular adhesion molecule, claudin (CLDN) 1, known to be involved in the migration and invasion o...
Source: Archives of Biochemistry and Biophysics - November 20, 2023 Category: Biochemistry Authors: Yuri Nagaoka Kotone Oshiro Yuta Yoshino Toshiyuki Matsunaga Satoshi Endo Akira Ikari Source Type: research
The effect of zoledronic acid on hip geometry in renal transplant recipients: a double-blind placebo-controlled randomized study
In renal transplant patients, bisphosphonates may prevent bone loss, but little is known about their effects on bone microarchitecture and geometrical hip parameters, as the key factors of bone stability. This... (Source: BMC Nephrology)
Source: BMC Nephrology - November 8, 2023 Category: Urology & Nephrology Authors: Alireza Dabbaghmanesh, Marzieh Bakhshayeshkaram, Sharareh Roshanzamir, Arzhang Naseri, Mohammad Mahdi Dabbaghmanesh, Seyed Taghi Heydari, Pedram Talehzadeh, Mohammad Hossein Dabbaghmanesh and Shahrokh Ezzatzadegan Jahromi Tags: Research Source Type: research
Denosumab and Mortality in a real ‐world setting – A Comparative Study
This study examined the association between Dmab and all-cause mortality compared to no treatment in subjects with a fracture and BPs in subjects without a fracture. The study population was from The Sax Institute's 45 and Up Study (n= 267,357), a prospective population-based cohort with questionnaire data linked to hospital admissions1, medication records2 and stored securely3.The new-user cohort design with propensity-score (PS) matching was implemented.In the Fracture cohort, Dmab and oral BP users were matched 1:2 to no treatment (Dmab: 617 women, 154 men, and oral BPs: 615 women, 266 men).In the No-fracture cohort,...
Source: Journal of Bone and Mineral Research - November 2, 2023 Category: Orthopaedics Authors: Dunia Alarkawi,
Thach Tran,
Weiwen Chen,
Lyn M March,
Fiona M Blyth,
Robert D Blank,
Dana Bliuc,
Jacqueline R Center Tags: Research Article Source Type: research
Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
Conclusion: Our analysis of FAERS database provided postmarketing surveillance data and revealed different strengths of reported AE signals between Dmab and ZA in some of their common AEs. It’s also worth noting that both drugs have potential off-label applications, which could introduce new AEs. This highlights the necessity for safety monitoring when using Dmab and ZA off-label. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - November 1, 2023 Category: Drugs & Pharmacology Source Type: research
Zoledronic acid
(Source: Reactions Weekly)
Source: Reactions Weekly - November 1, 2023 Category: Drugs & Pharmacology Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors
Bone is a frequent metastatic site in advanced non-small cell lung cancer (aNSCLC), with up to 40 % of patients harboring bone metastases (BM) at diagnosis [1–3]. Bone targeted agents (BTA) – such as zoledronic acid and denosumab – demonstrated to prevent and/or delay the occurrence of skeletal related events (SRE) in patients with BM, with a manageable toxicity profile and a significan t benefit also in terms of quality of life [4–7]. (Source: Lung Cancer)
Source: Lung Cancer - October 27, 2023 Category: Cancer & Oncology Authors: Sara Manglaviti, Marta Bini, Giulia Apollonio, Ernesto Zecca, Giulia Galli, Sabina Sangaletti, Alice Labianca, Elisa Sottotetti, Marta Brambilla, Mario Occhipinti, Claudia Proto, Arsela Prelaj, Diego Signorelli, Alessandro De Toma, Giuseppe Viscardi, Tere Source Type: research
Global Publication Trends and Research Hotspots of the Immune System and Osteoporosis: A Bibliometric and Visualization Analysis from 2012 to 2022
CONCLUSION: The influence of the immune system on OP has been widely studied, and the current research in this field focuses on the effect or mechanism of immune-related cytokines, signaling pathways and vitamin D on OP. Future research trends in this field should focus on the immune regulation mechanism and clinical transformation of zoledronic acid, chain fatty acids and the gut microbiota in OP.PMID:37881072 | DOI:10.2174/0118715303257269231011073100 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - October 26, 2023 Category: Drugs & Pharmacology Authors: Jinlong Zhao Yaoxing Dou Guihong Liang Hetao Huang Kunhao Hong Weiyi Yang Guanghui Zhou Bangxin Sha Jun Liu Lingfeng Zeng Source Type: research
Global Publication Trends and Research Hotspots of the Immune System and Osteoporosis: A Bibliometric and Visualization Analysis from 2012 to 2022
CONCLUSION: The influence of the immune system on OP has been widely studied, and the current research in this field focuses on the effect or mechanism of immune-related cytokines, signaling pathways and vitamin D on OP. Future research trends in this field should focus on the immune regulation mechanism and clinical transformation of zoledronic acid, chain fatty acids and the gut microbiota in OP.PMID:37881072 | DOI:10.2174/0118715303257269231011073100 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - October 26, 2023 Category: Endocrinology Authors: Jinlong Zhao Yaoxing Dou Guihong Liang Hetao Huang Kunhao Hong Weiyi Yang Guanghui Zhou Bangxin Sha Jun Liu Lingfeng Zeng Source Type: research
